MQ
Therapeutic Areas
Sage Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ZURZUVAE (zuranolone) | Postpartum Depression | Approved |
| SAGE-718 | Cognitive Impairment - Huntington's Disease | Phase 2 |
| SAGE-324 | Essential Tremor | Phase 2 |
| SAGE-689 | Not Disclosed | Phase 1 |
| SAGE-904 | Not Disclosed | Preclinical |
Leadership Team at Sage Therapeutics
BE
Barry E. Greene
Chief Executive Officer
KL
Kimberly Lee
Chief Corporate Affairs Officer
CB
Chris Benecchi
Chief Commercial Officer
LG
Laura Gault
Chief Medical Officer
JD
Jim Doherty
Chief Development Officer
AR
Al Robichaud
Chief Scientific Officer
KS
Kevin Starr
Chairman of the Board